Presence of serum RalA and serum p53 autoantibodies in 1833 patients with various types of cancer
This article was originally published here
Int J Clin Oncol. October 11, 2021. doi: 10.1007 / s10147-021-02045-0. Online ahead of print.
BACKGROUND: RalA is a member of the Ras superfamily of small GTPases. Anti-RalA autoantibodies (s-RalA-Abs) act as tumor markers in various types of cancer and are negatively associated with p53 autoantibodies (s-p53-Abs). This study aimed to assess the relationship between s-RalA-Abs and s-p53-Abs in various types of cancer.
METHODS: A total of 1833 cancer patients (esophageal cancer, 172; hepatocellular carcinoma, 91; lung cancer, 269; stomach cancer, 317; colon cancer, 262; breast cancer, 364; and prostate cancer, 358) and 73 healthy subjects were enrolled in the study. The levels of s-RalA-Abs and s-p53-Abs were analyzed using an enzyme-linked immunosorbent assay, and the positivity rates and relationships between the two autoantibodies were assessed. The cut-off values for s-RalA abs and s-p53 abs were defined as mean + 2 standard deviation and values above the cut-off values were defined as positive.
RESULTS: Titers in all cancer types were significantly higher than controls (P <0.01). The positivity rates for s-RalA-Abs ranged from 11.7% to 21.5%, and those for s-p53-Abs ranged from 12% to 28.5%. A combined assay of the two antibodies revealed positivity rates of 20.9 and 44.2%. In stage 0 / I / II tumors, the positivity rates of the combination of the two antibodies varied between 21.5 and 42.3%. The two autoantibodies were complementary in prostate and breast cancers, but independent in the other carcinomas.
CONCLUSION: The combined use of s-RalA-Abs and s-p53-Abs tended to increase the positivity rate in all cancers, including stage 0 / I / II cancers.
PMID: 34632560 | DOI: 10.1007 / s10147-021-02045-0